The 35th CINP World Congress of Neuropsychopharmacology

講演情報

[CINP2024] Poster Session

CINP2024 » Poster Session

Schizophrenia 5 - Clinical (3)

2024年5月26日(日) 13:30 〜 14:30 CINP Poster Session Hall (Lobby Gallery)

[P503] Evenamide as add-on treatment for treatment-resistant schizophrenia (TRS) patients not benefiting from antipsychotics: design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled clinical trial

*Ravi Anand1, Alessio Turolla2, Giovanni Chinellato2, Rodolfo Giuliani2, Richard Hartman3 (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

キーワード:Treatment resistant schizophrenia, Phase 3 study, glutamate modulation, add-on treatment, evenamide

抄録パスワード認証
抄録の閲覧にはパスワードが必要です。パスワードを入力して認証してください。

パスワード